ANZCTR search results

By estimating the heparin concentration using the relationship between activated clotting time and estimated heparin concentration, it should be possible to improve the ability to reverse heparin at the end of cardiac surgery. The current practice of 1:1 dosing is suboptimal and leads to systematic overdosing. Lower ratios have been shown to provide adequate reversal with reduced bleeding risk. Individualised approaches using point-of-care testing and mathematical models show promise for optimisation, but there are few randomised trials despite widespread clinical use.

This study looks at when beta blockers are given to patients having a CT coronary angiogram (CTCA). Some patients take beta blockers before arriving for their scan, while others receive them once they are in the imaging deparement. The purpose of this study is to compare how these two approaches affect scan preparation and timing. we think that giving beta blockers before arrival will reduce delays and make the process smoother.

This is a Phase 1, four-part clinical trial in healthy adult participants to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SPT-320, an investigational oral prodrug of agomelatine. Part C is a food-effect crossover study designed to evaluate how a standard meal influences the pharmacokinetics of SPT-320 and Agomelatine.

This study is investigating whether providing different types of information about the costs of a diagnostic test influences ICU doctors’ test-ordering behaviour. You are eligible for this study if you are a registered medical practitioner and have worked in an adult or paediatric ICU in Australia or New Zealand in the previous 24 months. Taking part in this study will involve reading some information about the costs associated with diagnostic testing and a hypothetical scenario describing a patient commonly seen in ICUs. You will then be asked to complete an online questionnaire about which tests you would request for the patient in the scenario and provide some background information about yourself. The findings of this study will inform future projects aiming to improve appropriate testing in the ICU.

This study is investigating whether providing different types of information about the costs of a diagnostic test influences ICU nurses’ test-ordering behaviour. You are eligible for this study if you are a registered nurse and have worked in an adult or paediatric ICU in Australia or New Zealand in the previous 24 months. Taking part in this study will involve reading some information about the costs associated with diagnostic testing and a hypothetical scenario describing a patient commonly seen in ICUs. You will then be asked to complete an online questionnaire about which tests you would request for the patient in the scenario and provide some background information about yourself. The findings of this study will inform future projects aiming to improve appropriate testing in the ICU.

Screen Your Way aims to increase cervical screening participation among under-and never screened Aboriginal and Torres Strait Islander women and people with a cervix. This will be done in partnership with Aboriginal Community Controlled Organisations (ACCHOs) by putting strategies in place to increase self-collection of cervical screening. The ultimate goal is to reduce cervical cancer incidence. The study will work with ACCHOs to co-design ways to increase self-collection, put them into practice, and evaluate how effective they are. The research team will work together with services and their community to develop strategies to support increasing the use of self-collection for cervical screening and other strategies to increase cervical screening. These tailored strategies will be put into practice (implemented) for 12 months. Findings from at least six services in NSW, QLD and NT will be combined and used to inform National scale up of self-collection and help other ACCHOS to roll-out self-collection.

This study will look at how people with ulcerative colitis (UC) respond to treatment with the medicine vedolizumab. It will take place across several centres and follow people in a real-world setting. The focus is on whether vedolizumab can help achieve “transmural response” or “transmural healing,” which means improvement and healing throughout the full thickness of the bowel wall, not just the inner lining. Participants will first receive vedolizumab through intravenous (IV) infusions to induce remission, and then continue with ongoing maintenance therapy. Ultrasound scans of the bowel (intestinal ultrasound, or IUS) will be used to measure changes and healing over time. The main aim is to understand how effective vedolizumab is at achieving deeper levels of healing in people with ulcerative colitis.

In residential aged care, up to 70% of residents will receive an antibiotic annually. However, there are high rates of inappropriate antibiotic use, including the inappropriate commencement of an antibiotic for infections where there is likely to be little or no benefit, and inappropriate choice of an antibiotic, its dose and duration. Behavioural science informed interventions have been shown to successfully reduce antibiotic prescribing in primary care. The primary purpose of this study is to test a bundled intervention consisting of social norm feedback, public commitment and consumer information to support improved antibiotic use.

Hypoglossal nerve stimulation (HNS) has been shown to be a safe and effective treatment option for patients with moderate to severe obstructive sleep apnea (OSA). However, since the introduction of HNS in clinical practice, approximately one third of the implanted patients do not demonstrate clinically meaningful improvement. This study will evaluate whether chronic ansa cerivalis stimulation (ACS) in combination with HNS during natural sleep will yield a clinical meaningful improvement for OSA patients.

This study aims to find out how the body absorbs, processes, and removes a new investigational drug called IRX616a (Cannabidiol) when given as a single inhaled dose in healthy adult volunteers, and to check the safety and tolerability of this treatment. Who is it for? You may be eligible for this study if you are a healthy adult aged 18 to 65 years with no significant medical conditions. You will need to undergo screening tests, including blood tests, heart monitoring, and a physical examination, to confirm you meet all the health requirements before enrolling. Study details All participants who choose to enrol in this study will be randomly allocated to receive a single inhaled dose of either IRX616a (Cannabidiol) or a placebo (a treatment with no active drug). The study drug will be given using a pressurised metered dose inhaler under the supervision of trained study staff. Participants will stay in the clinical research unit for at least 24 hours after dosing so that blood samples can be collected at multiple timepoints to measure levels of the drug in the body. Safety assessments, including monitoring for side effects, vital signs, heart tracings (electrocardiograms), laboratory tests, and questionnaires on mental health, will be performed before and after dosing, and again at a follow-up visit on Day 8. Higher doses of IRX616a may be studied in later groups if no safety concerns are identified in earlier groups. It is hoped this research will help determine the safety and tolerability of IRX616a and provide important information about how the drug behaves in the body to support the design of future studies.